Predictors of antipsychotic medication change

被引:8
|
作者
Sernyak, MJ
Leslie, D
Rosenheck, R
机构
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[2] VA NE Program Evaluat Ctr, New Haven, CT USA
[3] Yale Univ, Dept Psychiat, Sch Epidemiol & Publ Hlth, New Haven, CT 06520 USA
[4] Bristol Myers Squibb Co, New York, NY 10154 USA
来源
关键词
Schizophrenia; Health Promotion; Powerful Predictor; Clinical Variable; Service Utilization;
D O I
10.1007/BF02287330
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Atypical antipsychotics account for more than 60% of antipsychotic prescriptions written for the treatment of schizophrenia. While switching front one antipsychotic to another is a dynamic process, there has been no research on individual patient and institutional characteristics that predict antipsychotic switching. VA national administrative data were used to identify patients (it = 9660) with schizophrenia maintained on antipsychotic medication. Logistic regression was used to identify predictors of medication switching. Independent variables included information about service utilization, sociodemographic and clinical variables as well as institutional characteristics. This model was repeated for more specific switches between classes of medications and between specific medications. High levels of outpatient and inpatient service use were the most powerful predictors of switching. Sociodemographic, institutional, diagnostic, and functional measures were also predictive in some cases. Controlling for independent sociodemographic, diagnostic, and functional measures, frequency of clinical contact was the most robust predictor of switching antipsychotics.
引用
收藏
页码:85 / 94
页数:10
相关论文
共 50 条
  • [41] Antipsychotic medication adherence in schizophrenia
    Byerly, Matthew J.
    Nakonezny, Paul A.
    Lescouflair, Emmeline
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2007, 30 (03) : 437 - +
  • [42] Weight gain and antipsychotic medication
    Blackburn, GL
    JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 : 36 - 41
  • [43] Antipsychotic Medication and QT Prolongation
    Chohan, Paramdip Singh
    Mittal, Raman
    Javed, Afzal
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2015, 31 (05) : 1269 - 1271
  • [44] Antipsychotic medication in schizophrenia: a review
    Lally, John
    MacCabe, James H.
    BRITISH MEDICAL BULLETIN, 2015, 114 (01) : 169 - 179
  • [45] Antipsychotic medication and venous thrombosis
    Thomassen, R
    Vandenbroucke, JP
    Rosendaal, FR
    BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 : 63 - 66
  • [46] HISTORY OF THE DEVELOPMENT OF ANTIPSYCHOTIC MEDICATION
    FRANKENBURG, FR
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 1994, 17 (03) : 531 - 540
  • [47] Antipsychotic medication use in Australia
    Hollingworth, Samantha
    Nissen, Lisa
    Robinson, Maxine
    Hall, Wayne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S108 - S108
  • [48] The Effect of Financial Incentives on Adherence to Antipsychotic Depot Medication: Does It Change Over Time?
    Pavlickova, Hana
    Bremner, Stephen A.
    Priebe, Stefan
    JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (08) : E1029 - E1034
  • [49] Association between antipsychotic medication and clinically relevant weight change: meta-analysis
    Campforts, Bea
    Drukker, Marjan
    Crins, Joost
    van Amelsvoort, Therese
    Bak, Maarten
    BJPSYCH OPEN, 2023, 9 (01):
  • [50] Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
    Blackman, Rachael K.
    Dickinson, Dwight
    Eisenberg, Daniel P.
    Gregory, Michael D.
    Apud, Jose A.
    Berman, Karen F.
    SCHIZOPHRENIA RESEARCH-COGNITION, 2022, 27